JPRN-jRCT2031210043进行中（未招募）2 期
Multicenter investigator-initiated phase II trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration - FORTUNE trial
Takahashi Masamichi0 个研究点目标入组 45 人开始时间: 2021年4月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Subjects with histologically or cytologically confirmed metastatic, unresectable, or recurrent solid tumor who agree to provide an archival tumor sample, a residual biopsy sample, or a fresh tumor biopsy sample
- •2) Ineffective to or intolerant to initial treatment, or for which standard treatment is no longer available
- •3) Participants with an FGFR gene alteration detected by NGS panel, who fall under one of the categories of groups A to C defined as below.
- •Group A: FGFR1-3 fusion
- •Group B: FGFR1-3 specific activating mutations as below;
- •FGFR1: P150S, T340M, R445W, N546K, K656E
- •FGFR2: C62Y, A67V, N82K, D101Y, E160K, E163K, M186T, R203H, R210Q, Q212K, R251Q, S252W, P253R, P253L, A264T, W290C, K310R, Y328N, G364E, Y375C, C382R, A389T, V392A, R399Q, H416R, I422V, H544Q, N549H, N549K, N549D, N549S, L560F, K659E, K659N, R664W, E718K, S791T
- •FGFR3: G380E, G380R, A391E, K650T, K650E, K650Q, K650N
- •Group C: FGFR1-3 activating mutation not applicable to group B, or FGFR1, 2 gene amplification
- •4) For Group D, participants with cholangiocarcinoma who have previously received a selective FGFR inhibitor other than E7090 and have demonstrated progressive disease or resistance
- •5) Age >= 20 years
- •6) Karnofsky Performance Status (KPS) >= 70 for patients with primary CNS tumors. Performance Status (ECOG) 0-1 for patients with non-primary CNS tumors
- •7) For patients with non-primary CNS tumors, they have at least 1 lesion of >= 10 millimeter (mm) in the longest diameter for a non-lymph node or >= 15 mm in the short-axis diameter for a lymph node that is considered as serially measurable according to RECIST v1.1 using computerized tomography or magnetic resonance imaging (CT or MRI) within 28 days of enrollment. However, lesions that have received local treatment such as external-beam radiation therapy (EBRT) or radiofrequency ablation (RFA) must have progressed after these local treatment to count as measureable lesion
- •8) Participants with primary CNS tumors must meet all of the following criteria:
- •(1) Have received prior treatment including radiation and/or chemotherapy, as recommended or appropriate for the CNS tumor type
- •(2) Have >= 1 site of bi-dimensionally measurable disease (confirmed by magnetic resonance imaging (MRI) and evaluable by RANO criteria), with the size of at least one of the measurable lesions >= 1 cm in each dimension and noted on more than one imaging slice. Imaging study performed within 28 days before enrollment
- •(3) Must be neurologically stable based on neurologic exam at least for the last 7 days prior to enrollment. (based on medical examination/interview)
- •9) Laboratory tests performed within 28 days prior to enrollment (the same day of the week 4 weeks prior to the enrollment date is acceptable) fulfill the following (1)-(10), without any administration of granulocyte colony-stimulating factor (G-CSF formulation) or blood transfusion within 14 days before the blood collection date
- •(1) Absolute neutrophil count >= 1,500/mm^3
- •(2) Platelet count >= 10.0 x 10^4/mm^3
- •(3) Hemoglobin >= 8.0 g/dL
- •(4) Total bilirubin <= 2.25 mg/dL
- •(5) AST <= 90 U/L; if intrahepatic cholangiocarcinoma or liver metastasis present, <= 150 U/L
- •(6) ALT <= 126 U/L (men)/<= 69 U/L (women); if intrahepatic cholangiocarcinoma or liver metastasis present, 210 U/L (men)/<= 115 U/L (women)
- •(7) Creatinine <= 1.6 mg/dL (men)/<= 1.2 mg/dL (women)
- •(8) International normalized ratio (INR) <=1.5
- •(9) Corrected calcium <= 10.1 mg/
排除标准
- •1) Participants with brain or subdural metastases
- •2) Participants with leptomeningeal metastasis
- •3) Participants with primary spinal cord tumors
- •4) Participants with primary CNS tumor located in either cerebellum, brainstem, pituitary gland, optic nerve or olfactory nerve
- •5) Positive for either human immunodeficiency virus (HIV) antibody, HBs antigen, or HCV antibody (patients with positive HCV antibody but no detectable HCV-RNA are not excluded)
- •6) Negative for HBs antigen, but positive for HBs antibody or HBc antibody, and also positive for HBV-DNA quantification (not excluded if HBV-DNA is below detection sensitivity)
- •7) Child-Pugh score B or C
- •8) Participants with pericardial effusion, pleural effusion, or ascites requiring treatment
- •9) Have any of the following ocular diseases
- •a)Grade 2 or higher corneal disorders
- •b)Active retinopathy (e.g., age-related macular degeneration, central serous chorioretinal disease, retinal tear)
- •10) Participants whose toxicity of previous treatment has not recovered to Grade 1 or lower per Common Terminology Criteria for Adverse Events (CTCAE v5.0), except for alopecia, infertility, and the laboratory test results listed in the inclusion criteria
- •11) Participants who received a prior selective FGFR inhibitor in the recurrent/metastatic disease setting; except for patients with cholangiocarcinoma harboring FGFR2 fusion (Arm D). Note that prior use of a multi-kinase inhibitor which includes anti-FGFR activity is acceptable after review by the lead investigator
- •12) Participants who are receiving CYP3A inhibitors or inducers and must continue the drug due to underlying conditions during the study treatment period. If patients are to be enrolled, they must discontinue the drug at least 7 days prior to enrollment of this study
- •13) The presence of FGFR gatekeeper mutations as follows:
- •FGFR1 V561, FGFR2 V564/565, FGFR3 V555/557, FGFR4 V550
- •14) The presence of any of the following coexisting driver gene abnormalities:
- •-Genetic mutations (excluding VUS): KRAS, NRAS, EGFR, and BRAF V600
- •-Gene translocations ALK, ROS1, and NTRK
- •15) Impairment of gastrointestinal (GI) function or GI disease that may significantly after the absorption of oral E7090 (ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection)
研究者
相似试验
进行中（未招募）
2 期
Phase II multicenter investigator initiated trial of Convection-enhanced delivery of Nimustine Hydrochloride against brainstem gliomasJPRN-jRCT2021190003Tominaga Teiji30
进行中（未招募）
2 期
A prospective, multicenter phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients with relapsed/refractory transformed aggressive LymphomaC83.3Diffuse large B-cell lymphomaDRKS00023793niversitätsmedizin der Johannes Gutenberg-Universität Mainz26
进行中（未招募）
1 期
A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma.Malignant B-cell lymphomaMedDRA version: 21.0Level: PTClassification code 10003903Term: B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002373-59-DEniversity Medical Center of the Johannes Gutenberg University Mainz64
进行中（未招募）
1 期
A multicenter, randomized, phase II clinical trial to evaluate the effect of Avastin in combination with neoadjuvant treatment regimens on the molecular and metabolic characteristics and changes in the primary tumors with reference to the obtained responses in patients with large primary HER2 negative breast cancers. - Neo-AvaHER2 negative breast cancerEUCTR2008-003006-34-NOOslo Universitetssykehus200
招募中
2 期
Efficacy of Polyglycolic Acid Sheet on the clinical course of anastomotic leakage after gastrectomy in patients with gastric cancerJPRN-jRCTs042210090Kodera Yasuhiro320